IMU-838

DRUG4 trials

Sponsors

Immunic AG, University Hospitals Coventry and Warwickshire NHS Trust

Conditions

COVID-19Covid 19Multiple SclerosisUlcerative Colitis

Phase 2

Phase 2 Dose-finding IMU-838 for Ulcerative Colitis

TerminatedNCT03341962

Immunic AGUlcerative Colitis

Start: 2018-03-15End: 2022-11-16Updated: 2024-03-05

A Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator's Choice of Standard of Care Therapy, in Patients With Coronavirus Disease 19 (COVID-19)

CompletedNCT04379271

Immunic AGCOVID-19

Start: 2020-06-11End: 2021-02-23Updated: 2024-11-13

IMU-838 and Oseltamivir in the Treatment of COVID-19

CompletedNCT04516915

University Hospitals Coventry and Warwickshire NHS TrustCovid 19

Start: 2020-06-15End: 2022-09-21Updated: 2023-08-22

Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis

Active, not recruitingNCT05054140

Immunic AGMultiple Sclerosis

Start: 2021-09-30End: 2025-01-07Target: 450Updated: 2024-04-29

Related Papers

Vidofludimus Calcium in Patients With Moderate-to-Severe Ulcerative Colitis: A Randomized, Placebo-Controlled, Phase 2 Trial

Clinical and Translational Gastroenterology2025-01-10

Prospective, randomised, parallel-group, open-label study to evaluate the effectiveness and safety of IMU-838, in combination with oseltamivir, in adults with COVID-19: the <b>IONIC</b> trial protocol

BMJ Open2022-11-015 citations

Safety and Efficacy of Vidofludimus Calcium in Patients Hospitalized with COVID-19: A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial.

2022-10-1512 citations

A double‐blind, randomized, placebo‐controlled phase 2 trial evaluating the selective dihydroorotate dehydrogenase inhibitor vidofludimus calcium in relapsing‐remitting multiple sclerosis

Annals of Clinical and Translational Neurology2022-06-1420 citations

The Selective Oral Immunomodulator Vidofludimus in Patients with Active Rheumatoid Arthritis: Safety Results from the COMPONENT Study

Drugs in R&D2019-10-1629 citations